

























































published: 01 April 2014
doi: 10.3389/fendo.2014.00039
The role of pregnancy-associated hormones in the
development and function of regulatory B cells
Damián Muzzio, Marek Zygmunt and Federico Jensen*





Marta Letizia Hribal, University of
Catanzaro Magna Graecia, Italy
Amanda J. MacFarlane, Health
Canada, Canada




Laboratory, Department of Obstetrics





During mammalian pregnancy, highly specialized mechanisms of immune tolerance are
triggered in order to allow the semi-allogeneic fetus to grow within the maternal uterus in
harmony with the maternal immune system. Among other mechanisms, changes in the
endocrine status have been proposed to be at least part of the machinery responsible for
the induction of immune tolerance during pregnancy. Indeed, pregnancy-associated hor-
mones, estradiol, progesterone, and human chorionic gonadotropin are known to confer
immune suppressive capacity to innate as well as adaptive immune cells. Regulatory B
cells, a subpopulation of B lymphocytes with strong immunosuppressive functions, were
shown to expand during pregnancy. Furthermore, it is well-known that some women suffer-
ing from multiple sclerosis, significantly improve their symptoms during pregnancy and this
was attributed to the effect of female sex hormones. Accordingly, estradiol protects mice
from developing experimental autoimmune encephalomyelitis by triggering the expansion
and activation of regulatory B cells. In this review, we discuss different mechanisms asso-
ciated with the development, activation, and function of regulatory B cells with a special
focus on those involving pregnancy-associated hormones.
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INTRODUCTION
Pregnancy in mammals is accompanied by profound changes and
adaptations in the endocrine as well as the immune systems. These
adaptations are necessary to allow the semi-allogeneic fetus to
grow within the maternal uterus. However, in some cases, they
may influence the course of pre-existing pathologies, as for the case
of autoimmune diseases. In this regard, it is known that women
suffering from a pre-existing autoimmune disease demonstrate
changes in disease expression during pregnancy and this has been
associated with changes in female sex hormones.
Early in pregnancy, just after conception has taken place, a sys-
temic rise of progesterone (P4) and estradiol (E2) levels produced
by corpora lutea (CL) in the ovary is evidenced. These hormones
promote modifications of the uterine epithelium that allow a
proper interaction with the blastocyst ensuring embryo implanta-
tion. Once the embryo is implanted, trophoblast cells produce and
secrete increasing levels of human chorionic gonadotropin (hCG),
which on the one side stimulates the CLs to continue producing
progesterone, estradiol (E2), and estrone (E1) (1) and on the other
side promotes angiogenesis in the uterine endothelium (2) as well
as trophoblast migration and invasion into the uterine wall (3).
Besides these widely accepted functions of female sex hormones
in coordinating and controlling anatomical modifications asso-
ciated with gravity, abundant evidence has also highlighted their
role in shaping immune cells toward a transient state of tolerance
necessary for the maintenance of pregnancy (4).
Indeed, a major challenge faced by the maternal immune sys-
tem during pregnancy is precisely one of the most important
immunological riddles. The mother’s immune system has to accept
a semi-allogeneic fetus expressing foreign antigens through a state
of immunological tolerance. At the same time, the mother and the
fetus should be properly protected against the threat of infections.
To achieve this, the immune machinery must be strictly regulated
during the different stages of pregnancy. Several cell types with
regulatory capacities have been described among T cells and B
cells. Though the function of regulatory T cells (Tregs) in preg-
nancy has been extensively studied (5, 6), the role of regulatory B
cells in this context is still a novel field to be explored.
REGULATORY B CELLS AND THEIR EMERGING ROLE IN THE
CONTEXT OF PREGNANCY
The first reports linking suppressive activities to B cells arose from
experiments in guinea pigs, in which the transfer of B-cell-depleted
splenocytes failed to inhibit delayed-type hypersensitivity (DTH)
skin reactions (7, 8). More recently, strong evidence of the exis-
tence of B cells with suppressive capacities emerged in a murine
model of multiple sclerosis (MS) called experimental autoimmune
encephalomyelitis (EAE). In this model, mice lacking B cells suffer
an exacerbated form of the disease (9). Later on, Fillatreau et al.
showed similar results in EAE mice where the B cells are unable
to produce the anti-inflammatory cytokine, IL-10 (10). From this
point, the idea that B cells could be more than just antibody-
producing cells and could regulate the immune responses in an
IL-10-dependent fashion, started to be reinforced.
In both mouse and humans, different regulatory B-cell popula-
tions have been described. There is still controversy regarding their
phenotype, but all of them show necessarily an in vivo suppressing
capacity and their hallmark is the production of IL-10. In mice,
Evans and co-authors have described a subset of Transitional T2
B cells with CD21hiCD23+ phenotype, able to synthesize IL-10
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after stimulation of CD40 (11). Almost simultaneously, Yanaba
et al. associated a CD5+CD1d+ B-cell population with the ability
to produce IL-10 after stimulation with PMA and ionomycin, this
population was named regulatory B10 cells (12). In humans, the
phenotype is less clear. Blair and colleagues have found within the
CD19+CD24+CD38hi population, cells capable of suppressing,
through IL-10 production, the differentiation of Th1 T cells after
CD40 stimulation (13). Other authors confer the CD24hiCD27+
phenotype, which parallels the regulatory B10 cells in mouse, to
B cells with the ability to inhibit pro-inflammatory responses via
IL-10 secretion (14).
In the context of pregnancy, it was not until recently that a
role for regulatory B cells has been introduced. In a murine model
of pregnancy loss, Jensen et al. showed that CD19+CD5+CD1d+
regulatory B10 cells are diminished in the abortion-prone animals,
when compared to those with normal pregnancies. Moreover,
emulating the abortion preventing capacity of IL-10 admin-
istration (15), the transfer of IL-10-producing regulatory B10
cells was capable of reverting fetus rejection in otherwise abort-
ing animals (16). The same group found that a population of
CD19+CD24hiCD27+ regulatory B cells increases in the first
trimester of pregnancy. Interestingly, the levels of these cells in
patients suffering from spontaneous abortions remain as low as in
non-pregnant women (17).
It is not yet clear why and how these changes in regulatory B
cells during pregnancy are produced. The fact that B cells express
receptors for hormones playing a fundamental role during preg-
nancy, especially hCG and E2, highlights the importance of fur-
ther analyzing the interaction of these hormones with regulatory
B cells.
FEMALE SEX HORMONES AS MODULATORS OF REGULATORY
B CELLS ACTIVATION AND FUNCTION
As mentioned above, female sex hormones have long been sus-
pected to influence immune responses. A strong clue for a role
for female sex hormones in immunity is the fact that women are
much more susceptible to developing autoimmune diseases than
men (18, 19). In keeping with this, it is also well-documented
that the symptoms of autoimmune diseases during pregnancy,
when levels of female sex hormones are drastically modified,
are significantly affected. In this regard, women suffering from
autoimmune diseases depending on polyclonal B-cell activation
and circulating immune complexes such as systemic lupus erythe-
matosus (SLE) usually worsen during pregnancy (20, 21). How-
ever, other inflammation-driven conditions, such as rheumatoid
arthritis (RA) or MS, are reported to ameliorate (22).
The hCG is a glycoprotein hormone synthesized by the syn-
cytiotrophoblast immediately after embryo implantation. HCG
secretion is mandatory for the maintenance of the E2 and P4 pro-
duction by the corpus luteum during pregnancy until the placenta
is developed and takes over the production of these hormones (23).
Beside this fundamental role, in the past years, evidence has accu-
mulated demonstrating an immunomodulatory capacity of hCG
hormone on T cells (24–26), uNK cells (27), among others (28,
29). A recent work shifts the focus to the regulatory B cells (17).
It has been demonstrated that not only up to 95% of the
CD19+CD24hiCD27+ regulatory B cells express the receptor for
hCG (LH/hCGR) but that the addition of a human recombinant
hCG to pure isolated CD19+ B cells in vitro induced a strong
production of the potent anti-inflammatory and regulatory B-cell
hallmark, IL-10 (17).
Based on these results, the authors have proposed that hCG may
drive an expansion of IL-10-producing regulatory B cells during
normal pregnancy, thus controlling undesired immune activation
that may compromise pregnancy well-being. Indeed, B cells from
pregnant women undergoing normal pregnancies but not from
patients suffering spontaneous pregnancy loss were able to sup-
press TNF-α production, a classic pro-inflammatory cytokine, by
activated T cells (Figure 1) (17).
A very interesting phenomenon concerning the relationship
between female sex hormones and regulatory B cells is the clinical
remission that women suffering from MS experience during preg-
nancy (30). Subramanian et al. carried out a set of experiments
that led to the conclusion that sex hormones have a positive effect
on the activity of regulatory B cells that confer protection against
the symptoms of the disease. In a recent manuscript, Subramanian
and coworkers highlighted the role of regulatory B cells in the E2-
mediated protection of EAE in mice lacking Tregs (31). In those
mice, treatment with E2 provoked an augmentation of the pro-
duction of IL-10 in splenocytes and up-regulation of the negative
co-activation molecules, PDL1 and PDL2 on B cells. These results
were in concordance with previous reports in which regulatory
B cells conferred protection against EAE through production of
IL-10 (10, 32, 33).
There are two receptors that mediate the actions of E2: ER-
α and ER-β (34). It was first demonstrated that the protective
effects of E2 in EAE are mediated by ER-α (35). It is known that B
lymphocytes express ER-α and its activation affects the develop-
ment, survival, expansion, and maturation of these cells (36–38).
Recently, Bodhankar et al. showed that in the context of EAE, E2
acts in an ER-α-dependent way through B cells and not T cells.
Notably, these protective effects of E2 are lost in the absence of B
cells (39).
The scenario presented here centers on the regulatory B cells
that, as a consequence of the higher levels of E2 in pregnancy,
launch a set of suppressive mechanisms (IL-10 production, expres-
sion of PDL1) that favors immune tolerance (Figure 1). This
probable natural necessity in pregnancy may be one reason for the
clinical improvement observed in women with MS during gravity.
The steroid hormone progesterone is essential for the implan-
tation as well as for the development of an adequate uterine
structure, which involves changes in the growth and differenti-
ation of the epithelial and stromal cell layers of the endometrial
compartment that enables the maintenance of pregnancy (40).
Several studies have established the importance of this hormone
influencing the activity of various types of immune cells, such
as the ability to inhibit the presenting capacity of dendritic cells
(DCs) (41), monocytes, and macrophages (42, 43). Progesterone
also has an impact on the levels of galectin-1, which in turn
promotes the expansion and recruitment of suppressive uterine
DCs (44).
An immunomodulatory action of P4 on B cells has also been
described (45, 46). Treatment with P4 reduces the severity of EAE,
elevating the levels of IL-10 and the numbers of CD19+ cells (47)
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FIGURE 1 | Schematic representation depicting the influence of
female sex hormones in the activation and subsequent function of
regulatory B cells (Bregs). (A) Estradiol (E2), acting through estradiol
receptor alpha (ERα), induces the proliferation as well as the production
of IL-10 by regulatory B cells (Breg). In addition, E2 mediates the control
of T cells’ activation by B cells throughout a mechanism involving
PDL1/PD1 pathway. (B) Human chorionic gonadotropin (hCG) was
proposed to induce proliferation of regulatory B cells. Besides, this
hormone induces the production of IL-10 by B cells that in turn inhibit the
production of TNFα by T cells. (C) Progesterone (P4) induces the
production of the potent anti-inflammatory and Breg hallmark cytokine
IL-10 by B cells.
(Figure 1). This work invites us to speculate, that as for hCG
and E2, P4 could have an immunomodulatory action on regu-
latory B cells that may play a beneficial role in the remission of
MS during gravity and the phenomenon of regulated tolerance in
pregnancy.
CONCLUSION
We describe in this review a B-cell subset capable of being activated
and expanded upon hormone treatment, with the ability to sup-
press pro-inflammatory responses, leading to protection against
EAE or pregnancy loss. Many therapeutic approaches for the treat-
ment of autoimmune disease are centered on the depletion of B
cells. Therefore, unspecific deletion of B cells as in the case of Rit-
uximab™ treatment in MS patients (48) may result in the loss
of a potentially valuable subset of B cells that mediate a benefi-
cial anti-inflammatory environment associated with the transient
remission of the disease. A better understanding of the mecha-
nisms behind the activation and expansion of this population of
regulatory B cells can provide novel therapeutic strategies against
autoimmune diseases like MS as well as to pregnancy-associated
disturbances.
ACKNOWLEDGMENTS
This work was supported by a Grant from the Fritz Thyssen Foun-
dation (Az. 10.12.2.155) to Federico Jensen and by intramural
funding from Faculty of Medicine, Greifswald University.
REFERENCES
1. Arredond F, Noble LS. Endocrinology of recurrent pregnancy loss. Semin Reprod
Med (2006) 24:33–9. doi:10.1055/s-2006-931799
2. Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Münstedt K,
Rao CV, et al. Characterization of human chorionic gonadotropin as a novel

























































Muzzio et al. Pregnancy-associated hormones and regulatory B cells
angiogenic factor. J Clin Endocrinol Metab (2002) 87:5290–6. doi:10.1210/jc.
2002-020642
3. Zygmunt M, McKinnon T, Herr F, Lala PK, Han VKM. HCG increases tro-
phoblast migration in vitro via the insulin-like growth factor-II/mannose-6
phosphate receptor. Mol Hum Reprod (2005) 11:261–7. doi:10.1093/molehr/
gah160
4. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the
female sex hormones oestradiol and progesterone. FEMS Immunol Med Micro-
biol (2003) 38:13–22. doi:10.1016/S0928-8244(03)00202-5
5. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal
tolerance to the fetus. Nat Immunol (2004) 5:266–71. doi:10.1038/ni1037
6. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, et al.
Maternal alloantigens promote the development of tolerogenic fetal regulatory
T cells in utero. Science (2008) 322:1562–5. doi:10.1126/science.1164511
7. Katz SI, Parker D, Turk JL. B-cell suppression of delayed hypersensitivity reac-
tions. Nature (1974) 251:550–1. doi:10.1038/251550a0
8. Neta R, Salvin SB. Specific suppression of delayed hypersensitivity: the possible
presence of a suppressor B cell in the regulation of delayed hypersensitivity. J
Immunol (1974) 113:1716–25.
9. Wolf SD, Dittel BN, Hardardottir F, Janeway CA. Experimental autoimmune
encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med
(1996) 184:2271–8. doi:10.1084/jem.184.6.2271
10. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells reg-
ulate autoimmunity by provision of IL-10. Nat Immunol (2002) 3:944–50.
doi:10.1038/ni833
11. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ,
Ehrenstein MR, et al. Novel suppressive function of transitional 2 B cells in
experimental arthritis. J Immunol (2007) 178:7868–78.
12. Yanaba K, Bouaziz J, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B
cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent
inflammatory responses. Immunity (2008) 28:639–50. doi:10.1016/j.immuni.
2008.03.017
13. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehren-
stein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capac-
ity in healthy individuals but are functionally impaired in systemic lupus
erythematosus patients. Immunity (2010) 32:129–40. doi:10.1016/j.immuni.
2009.11.009
14. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, et al.
Characterization of a rare IL-10-competent B-cell subset in humans that paral-
lels mouse regulatory B10 cells. Blood (2011) 117:530–41. doi:10.1182/blood-
2010-07-294249
15. Chaouat G, Assal Meliani A, Martal J, Raghupathy R, Elliott JF, Elliot J, et al.
IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combi-
nation, and local defect in IL-10 production in this abortion-prone combination
is corrected by in vivo injection of IFN-tau. J Immunol (1995) 154:4261–8.
16. Jensen F, Muzzio D, Soldati R, Fest S, Zenclussen AC. Regulatory B10 cells
restore pregnancy tolerance in a mouse model. Biol Reprod (2013) 89:90.
doi:10.1095/biolreprod.113.110791
17. Rolle L, Memarzadeh Tehran M, Morell-García A, Raeva Y, Schumacher A, Har-
tig R, et al. Cutting edge: IL-10-producing regulatory B cells in early human
pregnancy. Am J Reprod Immunol (2013) 70:448–53. doi:10.1111/aji.12157
18. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated
population burden of selected autoimmune diseases in the United States. Clin
Immunol Immunopathol (1997) 84:223–43. doi:10.1006/clin.1997.4412
19. Gleicher N, Barad DH. Gender as risk factor for autoimmune diseases. J Autoim-
mun (2007) 28:1–6. doi:10.1016/j.jaut.2006.12.004
20. Zhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, et al. New-onset systemic
lupus erythematosus during pregnancy. Clin Rheumatol (2013) 32:815–22.
doi:10.1007/s10067-013-2180-z
21. Wei Q, Ouyang Y, Zeng W, Duan L, Ge J, Liao H. Pregnancy complicating sys-
temic lupus erythematosus: a series of 86 cases. Arch Gynecol Obstet (2011)
284:1067–71. doi:10.1007/s00404-010-1786-5
22. Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset
of rheumatoid arthritis. Arthritis Rheum (1992) 35:152–5. doi:10.1002/art.
1780350205
23. Dufau ML. The luteinizing hormone receptor. Annu Rev Physiol (1998)
60:461–96. doi:10.1146/annurev.physiol.60.1.461
24. Khil L, Jun H, Kwon H, Yoo JK, Kim S, Notkins AL, et al. Human chori-
onic gonadotropin is an immune modulator and can prevent autoimmune
diabetes in NOD mice. Diabetologia (2007) 50:2147–55. doi:10.1007/s00125-
007-0769-y
25. Dong M, Ding G, Zhou J, Wang H, Zhao Y, Huang H. The effect of trophoblasts
on T lymphocytes: possible regulatory effector molecules – a proteomic analysis.
Cell Physiol Biochem (2008) 21:463–72. doi:10.1159/000129639
26. Fuchs T, Hammarström L, Smith CI, Brundin J. In vitro induction of murine
suppressor T-cells by human chorionic gonadotropin.ActaObstet Gynecol Scand
(1980) 59:355–9. doi:10.3109/00016348009154093
27. Kane N, Kelly R, Saunders PTK, Critchley HOD. Proliferation of uterine nat-
ural killer cells is induced by human chorionic gonadotropin and mediated
via the mannose receptor. Endocrinology (2009) 150:2882–8. doi:10.1210/en.
2008-1309
28. Wan H, Versnel MA, Leijten LME, van Helden-Meeuwsen CG, Fekkes D, Leenen
PJM, et al. Chorionic gonadotropin induces dendritic cells to express a tolero-
genic phenotype. J Leukoc Biol (2008) 83:894–901. doi:10.1189/jlb.0407258
29. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A. Human chori-
onic gonadotropin contributes to maternal immunotolerance and endometrial
apoptosis by regulating Fas-Fas ligand system. J Immunol (2003) 171:2305–13.
30. Patas K, Engler JB, Friese MA, Gold SM. Pregnancy and multiple sclerosis: feto-
maternal immune cross talk and its implications for disease activity. J Reprod
Immunol (2013) 97:140–6. doi:10.1016/j.jri.2012.10.005
31. Subramanian S, Yates M, Vandenbark AA, Offner H. Oestrogen-mediated
protection of experimental autoimmune encephalomyelitis in the absence of
Foxp3+ regulatory T cells implicates compensatory pathways including reg-
ulatory B cells. Immunology (2011) 132:340–7. doi:10.1111/j.1365-2567.2010.
03380.x
32. Matsushita T, Yanaba K, Bouaziz J, Fujimoto M, Tedder TF. Regulatory B cells
inhibit EAE initiation in mice while other B cells promote disease progression.
J Clin Invest (2008) 118:3420–30. doi:10.1172/JCI36030
33. Kala M, Rhodes SN, Piao W, Shi F, Campagnolo DI, Vollmer TL. B cells
from glatiramer acetate-treated mice suppress experimental autoimmune
encephalomyelitis. Exp Neurol (2010) 221:136–45. doi:10.1016/j.expneurol.
2009.10.015
34. Matthews J, Gustafsson J. Estrogen signaling: a subtle balance between ER alpha
and ER beta. Mol Interv (2003) 3:281–92. doi:10.1124/mi.3.5.281
35. Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn
EP, et al. The protective effect of 17beta-estradiol on experimental autoimmune
encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol
(2003) 163:1599–605. doi:10.1016/S0002-9440(10)63516-X
36. Kincade PW, Medina KL, Payne KJ, Rossi MI, Tudor KS, Yamashita Y, et al. Early
B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev
(2000) 175:128–37. doi:10.1111/j.1600-065X.2000.imr017502.x
37. Grimaldi CM, Michael DJ, Diamond B. Cutting edge: expansion and activation
of a population of autoreactive marginal zone B cells in a model of estrogen-
induced lupus. J Immunol (2001) 167:1886–90.
38. González DA, Díaz BB, Rodríguez Pérez MDC, Hernández AG, Chico BND, de
León AC. Sex hormones and autoimmunity. Immunol Lett (2010) 133:6–13.
doi:10.1016/j.imlet.2010.07.001
39. Bodhankar S, Wang C, Vandenbark AA, Offner H. Estrogen-induced protection
against experimental autoimmune encephalomyelitis is abrogated in the absence
of B cells. Eur J Immunol (2011) 41:1165–75. doi:10.1002/eji.201040992
40. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, et al.
Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormal-
ities. Genes Dev (1995) 9:2266–78. doi:10.1101/gad.9.18.2266
41. Butts CL, Shukair SA, Duncan KM, Bowers E, Horn C, Belyavskaya E, et al.
Progesterone inhibits mature rat dendritic cells in a receptor-mediated fashion.
Int Immunol (2007) 19:287–96. doi:10.1093/intimm/dxl145
42. Alok A, Mukhopadhyay D, Karande AA. Glycodelin A, an immunomodulatory
protein in the endometrium, inhibits proliferation and induces apoptosis in
monocytic cells. Int J Biochem Cell Biol (2009) 41:1138–47. doi:10.1016/j.biocel.
2008.10.009
43. Hodson LJ, Chua ACL, Evdokiou A, Robertson SA, Ingman WV. Macrophage
phenotype in the mammary gland fluctuates over the course of the estrous
cycle and is regulated by ovarian steroid hormones. Biol Reprod (2013) 89:65.
doi:10.1095/biolreprod.113.109561

























































Muzzio et al. Pregnancy-associated hormones and regulatory B cells
44. Blois SM, Ilarregui JM, Tometten M, Garcia M, Orsal AS, Cordo-Russo R, et al. A
pivotal role for galectin-1 in fetomaternal tolerance. NatMed (2007) 13:1450–7.
doi:10.1038/nm1680
45. Canellada A, Blois S, Gentile T, Margni Idehu RA. In vitro modulation of pro-
tective antibody responses by estrogen, progesterone and interleukin-6. Am J
Reprod Immunol (2002) 48:334–43. doi:10.1034/j.1600-0897.2002.01141.x
46. Kyurkchiev D, Ivanova-Todorova E, Kyurkchiev SD. New target cells of the
immunomodulatory effects of progesterone. Reprod Biomed Online (2010)
21:304–11. doi:10.1016/j.rbmo.2010.04.014
47. Yates MA, Li Y, Chlebeck P, Proctor T, Vandenbark AA, Offner H. Prog-
esterone treatment reduces disease severity and increases IL-10 in experi-
mental autoimmune encephalomyelitis. J Neuroimmunol (2010) 220:136–9.
doi:10.1016/j.jneuroim.2010.01.013
48. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell deple-
tion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med
(2008) 358:676–88. doi:10.1056/NEJMoa0706383
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 12 February 2014; accepted: 14 March 2014; published online: 01 April 2014.
Citation:Muzzio D, Zygmunt M and Jensen F (2014) The role of pregnancy-associated
hormones in the development and function of regulatory B cells. Front. Endocrinol. 5:39.
doi: 10.3389/fendo.2014.00039
This article was submitted to Cellular Endocrinology, a section of the journal Frontiers
in Endocrinology.
Copyright © 2014 Muzzio, Zygmunt and Jensen. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org April 2014 | Volume 5 | Article 39 | 5
